至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

MCL1 and DEDD Promote Urothelial Carcinoma Progression.

Mol. Cancer Res.. 2019-03; 
HongAndrew L, GuerrieroJennifer L, DoshiMihir B, KynnapBryan D, KimWon Jun, SchinzelAnna C, ModisteRebecca, SchlauchAmy J, AdamRosalyn M, KwiatkowskiDavid J, BeroukhimRameen, LetaiAnthony, RosenbergJonathan E, HahnWilli
Products/Services Used Details Operation
PCR Cloning and Subcloning … Fortress Biotech, Pharmacyclics; has received honoraria from BMS, AstraZeneca, Chugai Pharma … by Genscript and sequence verified (Piscataway Township, NJ) … 1:500), beta-actin (C4; sc-47778; 1: 10,000) from Santa Cruz Biotechnology, V5/HRP (R961-25; … Get A Quote

摘要

Focal amplification of chromosome 1q23.3 in patients with advanced primary or relapsed urothelial carcinomas is associated with poor survival. We interrogated chromosome 1q23.3 and the nearby focal amplicon 1q21.3, as both are associated with increased lymph node disease in patients with urothelial carcinoma. Specifically, we assessed whether the oncogene that resides in 1q21.3 and the genes that reside in the 1q23.3 amplicon were required for the proliferation or survival of urothelial carcinoma. We observed that suppressing MCL1 or the death effector domain-containing protein (DEDD) in the cells that harbor amplifications of 1q21.3 or 1q23.3, respectively, inhibited cell proliferation. We also found ... More

关键词